Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel cell therapies to restore balance to the immune system, today announced the appointment of Pedro Huertas, [...]
Delivering on the promise of cell therapy
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel delivery approaches to cell therapy.
Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.